News & Updates

Iberdomide confers dermatologic benefit for SLE

15 Jun 2021 by

A high dose of the high-affinity cereblon ligand iberdomide delivered beneficial effects on the cutaneous manifestations of systemic lupus erythematosus (SLE), according to a phase II study presented at EULAR 2021.

Iberdomide confers dermatologic benefit for SLE

15 Jun 2021

Ceftazidime-avibactam brightens outlook in CRE bacteraemia

15 Jun 2021

Treatment with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae (CRE) bacteraemia appears to reduce the risk of death over 2 weeks when compared with colistin, according to a study.

Ceftazidime-avibactam brightens outlook in CRE bacteraemia

15 Jun 2021

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

15 Jun 2021

The fixed-dosing omadacycline strategy demonstrates consistent safety and efficacy in patients with community-acquired bacterial pneumonia (CABP), regardless of body mass index (BMI), according to a phase III trial.

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

15 Jun 2021

PAP-treated sleep apnoea tied to reduced COVID-19 risk

14 Jun 2021 by

Individuals with obstructive sleep apnoea (OSA) may have an increased risk of COVID-19, with the risk reducing with adherence to positive airway pressure (PAP) therapy, according to a study presented at ATS 2021.

PAP-treated sleep apnoea tied to reduced COVID-19 risk

14 Jun 2021

High-dose thiamine as IV push safe to administer

14 Jun 2021

Administering thiamine ≤200 mg as an intravenous (IV) push is safe, with no serious adverse events (AEs) seen, reveals a study.

High-dose thiamine as IV push safe to administer

14 Jun 2021

Pharmacists may help identify predictable ICI toxicities to improve cancer therapy

14 Jun 2021

A recent study has shown the necessary assistance pharmacists could provide in identifying predictable toxicities of immune checkpoint inhibitors (ICIs) that are related to gastrointestinal, endocrine, and dermatological toxicities, and fatigue.

Pharmacists may help identify predictable ICI toxicities to improve cancer therapy

14 Jun 2021

Henagliflozin-metformin combo a new therapeutic alternative for T2D

14 Jun 2021 by

Adding the sodium-glucose cotransporter-2 (SGLT2) inhibitor henagliflozin to metformin led to significant improvements in glycaemic control, body weight, and blood pressure (BP) in Chinese patients with type 2 diabetes (T2D) with insufficient response to metformin alone, a phase III study has shown.

Henagliflozin-metformin combo a new therapeutic alternative for T2D

14 Jun 2021

Short-term LDL-C change translates to reductions in long-term MACE risk

14 Jun 2021

In patients with acute coronary syndromes, undergoing a more intensive low-density lipoprotein cholesterol (LDL-C)–lowering therapy during the early disease phase leads to a significant decrease in the risk of long-term major adverse cardiac events (MACEs), according to a study. This benefit is more pronounced for patients with higher baseline and larger reduction in LDL-C levels.

Short-term LDL-C change translates to reductions in long-term MACE risk

14 Jun 2021

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

13 Jun 2021 by

In hospitalized COVID-19 patients with elevated D-dimer levels who were under stable condition, initial in-hospital anticoagulation using a therapeutic dose of rivaroxaban 20 mg did not improve clinical outcomes compared with standard prophylactic anticoagulation, according to the ACTION* trial presented at ACC.21 Meeting.

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

13 Jun 2021

Preoperative pirfenidone cuts risk of postoperative complications in IPF patients

13 Jun 2021

Preoperative treatment with pirfenidone results in a significant reduction in the risk of postoperative severe respiratory complications in patients with idiopathic pulmonary fibrosis (IPF), a study has shown.

Preoperative pirfenidone cuts risk of postoperative complications in IPF patients

13 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Iberdomide confers dermatologic benefit for SLE

Iberdomide confers dermatologic benefit for SLE

Ceftazidime-avibactam brightens outlook in CRE bacteraemia

Ceftazidime-avibactam brightens outlook in CRE bacteraemia

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

PAP-treated sleep apnoea tied to reduced COVID-19 risk

PAP-treated sleep apnoea tied to reduced COVID-19 risk

High-dose thiamine as IV push safe to administer

High-dose thiamine as IV push safe to administer

Pharmacists may help identify predictable ICI toxicities to improve cancer therapy

Pharmacists may help identify predictable ICI toxicities to improve cancer therapy

Henagliflozin-metformin combo a new therapeutic alternative for T2D

Henagliflozin-metformin combo a new therapeutic alternative for T2D

Short-term LDL-C change translates to reductions in long-term MACE risk

Short-term LDL-C change translates to reductions in long-term MACE risk

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

Preoperative pirfenidone cuts risk of postoperative complications in IPF patients

Preoperative pirfenidone cuts risk of postoperative complications in IPF patients